Home › Compound Library › Olanzapine (Zyprexa)

Olanzapine (Zyprexa)

Antipsychoticprescriptionoral · inferred

Thienobenzodiazepine atypical antipsychotic with broad receptor affinity: D2/D3/D4, 5-HT2A/2C, H1, M1-5, and alpha-1 antagonism. Highly effective for schizophrenia and bipolar mania but notorious for metabolic side effects, significant weight gain (avg 4-5 kg in 10 weeks), dyslipidemia, and diabetes risk. Metabolized by CYP1A2 (smoking induces clearance ~40%) and UGT. Available as oral, IM rapid-acting, and long-acting IM depot (Zyprexa Relhyprev).

Projected serum levels — 10 mg, once daily

Olanzapine (Zyprexa)
Olanzapine (Zyprexa) modeled serum levels, 10 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 4 days. 0 5 10 15 20 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 4
Olanzapine (Zyprexa) modeled serum levels with a loading dose of 23.8 mg, then 10 mg once daily The first dose is larger so levels approach steady state faster. 0 5 10 15 20 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 10 mg once daily (oral).

Loading schedule: 23.8 mg on day 1, then 10 mg once daily — reaching therapeutic levels sooner.

Modeled steady state after ~4 days: peak ≈ 12.6 mg, trough ≈ 8.1 mg body load. Population-based estimate over 15 days for a 10 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Antipsychotic
Route modeled
Oral
Model confidence
inferred
Half-life
30 h
Common dose
10 mg
Suggested maximum
20 mg/day
Reference dose range
5–20 mg (single dose)
Suggested cadence
once daily
Validated against
10 mg oral — Cmax 0.011 mg/L at 5 h

Documented interactions

  • danger
    1P-LSD (1-Propionyl-LSD) + Olanzapine (Zyprexa) Serotonin risk

    1P-LSD (1-Propionyl-LSD) and Olanzapine (Zyprexa) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) + Olanzapine (Zyprexa) Serotonin risk

    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) and Olanzapine (Zyprexa) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    3-MeO-PCP (3-Methoxyphencyclidine) + Olanzapine (Zyprexa) Serotonin risk

    3-MeO-PCP (3-Methoxyphencyclidine) and Olanzapine (Zyprexa) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    4-AcO-DMT (Psilacetin) + Olanzapine (Zyprexa) Serotonin risk

    4-AcO-DMT (Psilacetin) and Olanzapine (Zyprexa) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    5-HTP (5-Hydroxytryptophan) + Olanzapine (Zyprexa) Serotonin risk

    5-HTP (5-Hydroxytryptophan) and Olanzapine (Zyprexa) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine) + Olanzapine (Zyprexa) Serotonin risk

    5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine) and Olanzapine (Zyprexa) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental…

Serum checks 117 modeled interaction pairings for olanzapine (zyprexa) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial Tohen M et al. · American Journal of Psychiatry, 2005 DOI

    12-month RCT (431 patients) finding olanzapine superior to lithium for preventing bipolar relapse overall (30% vs 39%), particularly manic episodes, but with significantly more weight gain and metabolic effects.

  2. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia Conley RR, Mahmoud R · Journal of Clinical Psychiatry, 2001 DOI

    RCT demonstrating olanzapine superiority to chlorpromazine for treatment-resistant schizophrenia, with 7% meeting response criteria on olanzapine 25 mg/day versus 0% on chlorpromazine.

  3. Clinical pharmacokinetics of olanzapine Callaghan JT et al. · Clinical Pharmacokinetics, 1999 DOI

    Definitive PK study establishing olanzapine half-life of 21-54 hours (mean 33h), 60% oral bioavailability, CYP1A2-dependent metabolism (40% faster clearance in smokers), and linear pharmacokinetics.

3 published studies referenced in the app, each with a plain-language summary.